Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Orogenital ulcers, SLE and hydralazine

E Neville, P Y Graham, R A Brewis

    Postgraduate Medical Journal
    |June 1, 1981
    PubMed
    Summary

    Hydralazine can induce systemic lupus erythematosus, a condition causing arthritis and rash. Symptoms resolved after discontinuing the medication, highlighting drug-induced lupus.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A prolonged outbreak of invasive meningococcal disease in an extended Irish Traveller family across three Health Service Executive (HSE) areas in Ireland, 2010 to 2013.

    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2015
    Same author

    Detection of k-ras mutations in nonsmall cell lung-carcinoma.

    International journal of oncology·2011
    Same author

    Allelotype of non-small cell lung cancer.

    International journal of oncology·2011
    Same author

    Lung cancer * 8: Management of malignant mesothelioma.

    Thorax·2003
    Same author

    BTS guidelines for the management of malignant pleural effusions.

    Thorax·2003
    Same author

    BTS guidelines for the insertion of a chest drain.

    Thorax·2003

    Area of Science:

    • Pharmacology
    • Immunology
    • Dermatology

    Background:

    • Drug-induced systemic lupus erythematosus (DI-SLE) is a recognized adverse reaction to certain medications.
    • Hydralazine, a vasodilator, is a known culprit in the development of DI-SLE.

    Observation:

    • A patient presented with symptoms consistent with systemic lupus erythematosus, including arthritis and a purpuric rash.
    • The rash was notably present in sun-exposed areas, and the patient also exhibited orogenital and cutaneous ulcerations.
    • Laboratory tests revealed positive anti-nuclear antibody and DNA binding, indicative of autoimmune activity.

    Findings:

    • The patient's clinical manifestations, including arthritis and rash, were directly linked to hydralazine use.
    • Discontinuation of hydralazine led to the complete resolution of all observed symptoms.
    • This case confirms the causal relationship between hydralazine and the development of DI-SLE.

    Implications:

    • This case underscores the importance of considering drug-induced causes in patients presenting with lupus-like symptoms.
    • Awareness of hydralazine's potential to cause DI-SLE is crucial for clinicians prescribing this medication.
    • Prompt recognition and withdrawal of the offending agent are key to managing hydralazine-induced lupus erythematosus.

    Related Experiment Videos